The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess the drug's efficacy in reducing liver fat and its impact on body composition over a 26-week treatment period.
The M-ACCEL trial is a phase IIa study that evaluated the investigational oral drug HU6 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This trial aimed to assess the drug's efficacy in reducing liver fat and its impact on body composition over a 26-week treatment period. HU6 was tested in three daily doses: 150 mg, 300 mg, and 450 mg, alongside a placebo group for comparison.
The trial demonstrated that HU6 significantly reduced liver fat in patients with MASH. Patients receiving HU6 experienced reductions in liver fat content of 29.4%, 31.2%, and 27% for the 150 mg, 300 mg, and 450 mg doses, respectively, compared to only 6.7% in the placebo group—a statistically significant difference (P=0.005). More than half of the patients on HU6 achieved at least a 30% reduction in liver fat, far exceeding the 22% response rate in the placebo group. Importantly, these reductions occurred without loss of skeletal muscle mass, which is critical for managing weight-related liver diseases.
Additionally, HU6 impacted body composition, with the 450-mg dose leading to significant fat loss (–2.4 kg) compared to placebo (–0.9 kg). Muscle mass remained stable across all HU6 groups. HU6 functions as a controlled metabolic accelerator, increasing mitochondrial energy usage, and offers a promising oral treatment option for MASH with mild side effects and good safety profiles.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.